AVITA Medical, Inc. (RCEL): Price and Financial Metrics
RCEL Price/Volume Stats
| Current price | $8.30 | 52-week high | $21.70 |
| Prev. close | $8.57 | 52-week low | $8.01 |
| Day low | $8.01 | Volume | 251,800 |
| Day high | $8.36 | Avg. volume | 212,146 |
| 50-day MA | $14.92 | Dividend yield | N/A |
| 200-day MA | $14.51 | Market Cap | 213.37M |
RCEL Stock Price Chart Interactive Chart >
AVITA Medical, Inc. (RCEL) Company Bio
AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.
Latest RCEL News From Around the Web
Below are the latest news stories about AVITA MEDICAL INC that investors may wish to consider to help them evaluate RCEL as an investment opportunity.
AVITA Medical to Host Investor Webinar BriefingVALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on December 5, 2023, at 2:00 p.m. (PS |
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare ConferenceVALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time. A live webcast of the present |
AVITA Medical Updates Full Year 2023 GuidanceVALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer’s Value Analysis Committee (VAC) processes, driven by the expanded label application |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching for Friday morning! |
AVITA Medical, Inc. (NASDAQ:RCEL) Q3 2023 Earnings Call TranscriptAVITA Medical, Inc. (NASDAQ:RCEL) Q3 2023 Earnings Call Transcript November 9, 2023 AVITA Medical, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.53. Operator: Good day, and thank you for standing by. Welcome to the AVITA Medical Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. After […] |
RCEL Price Returns
| 1-mo | -48.09% |
| 3-mo | -50.09% |
| 6-mo | -10.66% |
| 1-year | -41.09% |
| 3-year | -58.85% |
| 5-year | -70.25% |
| YTD | -39.50% |
| 2023 | 107.88% |
| 2022 | -44.91% |
| 2021 | -35.52% |
| 2020 | -59.16% |
| 2019 | 712.50% |
Loading social stream, please wait...